NEW YORK, NY / ACCESSWIRE / August 28, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Curaleaf Holdings, Inc. (OTCMKT:CURLF)
Class Period: November 21, 2018 – July 22, 2019
Deadline: October 4, 2019
For more info: www.bgandg.com/curlf

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration (“FDA”); and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

2U, Inc. (NASDAQ:TWOU)
Class Period: February 25, 2019 – July 30, 2019,
Deadline: October 7, 2019
For more info: www.bgandg.com/twou

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) 2U faced increasing competition in online education and particularly regarding graduate programs; (2) 2U faced certain program-specific issues that negatively impacted its performance; (3) as a result, the Company’s business model was not sustainable; (4) 2U would slow its program launches; and (5) consequently, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Evolent Health, Inc. (NYSE:EVH)
Class Period: March 3, 2017 – May 28, 2019
Deadline: October 7, 2019
For more info: www.bgandg.com/evh

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Evolent’s partnership model did not align the Company’s interests with those of its partners, as the model was designed to inflate the Company’s revenue by extracting enormous administrative and management fees at the expense of its operating partners such as Passport; (2) Passport was struggling financially, particularly after Kentucky cut its reimbursement rates, and the partnership between Evolent and Passport was becoming increasingly unsustainable; (3) Evolent was draining Passport of functions, employees and money, to such an extent that Passport was left on the verge of insolvency; (4) Passport was conducting a bidding process for several months to sell itself to prevent liquidation; and (5) consequently, Defendants’ public statements were materially false and/or misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557351

NEW YORK, NY / ACCESSWIRE / August 28, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ:HSDT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Helius securities from November 9, 2017 and April 10, 2019, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/hsdt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

On January 25, 2019, Helius said that it had received a request for additional data and information from the U.S. Food and Drug Administration (the “FDA”) related to the its request for de novo classification and 510(k) clearance of its Portable Neuromodulation Stimulator (PoNS™) device. Following this news, Helius stock dropped $0.48 per share, or roughly 6%, to close at $7.13 on January 25, 2019.

On April 10, 2019, Helius disclosed that the U.S. Food and Drug Administration (“FDA”) had declined the Company’s request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device. The FDA stated that it lacked sufficient data to determine the relative contributions of the device and physical therapy in clinical studies. Following this news, Helius stock dropped $4.11 per share, or more than 66%, to close at $2.10 on April 10, 2019.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) that the clinical study on the use of PoNS did not produce statistically significant results regarding the effectiveness of the treatment; (2) that, as a result, the clinical study did not support the Company’s application for regulatory clearance; (3) that, as a result, the Company was unlikely to receive regulatory approval of PoNS; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/hsdt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Helius you have until September 9, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557336

TORONTO, ON / ACCESSWIRE / August 28, 2019 / Aquarius Surgical Technologies Inc. (CSE:ASTI) (“ASTI” or “the Company”), an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines in the field of urology, today announced financial results for the three-month period ended June 30, 2019. The full report is available on www.SEDAR.com.

All amounts expressed are in Canadian dollars. All comparisons are relative to the three-month period ended June 30, 2018.

Quarter Financial Highlights:

Total sales of $303,220 as compared to $27,514
Gross margin of $145,936 as compared to $1,360 due to the advancement in the equipment sales and rentals, plus an increase of $35,677 in fiber sales
Inventories of $243,204, down from $857,591
Net loss of $344,445 as compared to a net loss of $378,499
As at June 30, 2019, ASTI had $517,392 in cash and deposits as compared to $166,559

“We are quite pleased with our quarterly results, which nearly surpassed total sales of the last fiscal year,” said Gordon Willox, Founder & President of ASTI. “Last year we spent most of our time educating doctors on how to operate our lasers and held multiple training sessions across the USA. Now that our technology has been successfully tested by numerous well-regarded surgeons and institutions, we are focused on ramping upthe sales and are already securing new sales distribution agreements. We expect ASTI to show a significantly higher overall growth this year from both the laser equipment sales and the recurring revenue from the disposable fibers.”

ASTI is in the process of raising up to $2.5 million via a Private Placement offering, the net proceeds of which would go towards adding more sales teams to further grow the Company’s market presence.

About Aquarius Surgical Technologies Inc.

Aquarius Surgical Technologies (ASTI: CSE) is an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions also include clinical education, service, support and maintenance. ASTI is focused on increasing the availability of services for patients, enhancing the quality of patient care, improving operationally efficiencies and reducing total operational costs. Learn more by visiting the Investors tab on ASTI’s website https://surgicallasersinc.com/.

For more information, please contact:

Gordon Willox, President
Phone: 844-441-9090
Phone: 905-853-9090
gordonwillox@live.ca

Cathy Hume, Investor Relations
Phone: 416-868-1079 x 231
Email: cathy@chfir.com

Neither the CSE Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investors are cautioned that trading in the securities of the Corporation should be considered highly speculative. Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially. Aquarius Surgical Technologies Inc. will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Aquarius Surgical Technologies Inc.

Condensed Consolidated Interim Statement of Comprehensive Loss (Unaudited)
(Expressed in Canadian dollars) Three Months Ended

30-Jun-19

30-Jun-18

Sales

$

$

Equipment

225,728

–

Fiber sales

63,191

27,514

Equipment rental

13,060

–

Other

1,241

–

303,220

27,514

Cost of sales

157,284

26,154

Gross Margin

145,936

1,360

Expenses

General and administrative (Note 12)

378,565

364,510

Bank charges and interest

78,555

2,551

Amortization (Notes 5)

33,261

12,798

490,381

379,859

Net loss before other items

(344,445
)

(378,499
)

Other items: Interest income

3,381

–

Net loss for period

(341,064
)

(378,499
)

Loss per share, basic and diluted

$
(0.017
)

$
(0.020
)

Weighted average number of shares outstanding (Notes 8 and 13)

19,652,876

18,863,929

The accompanying notes form an integral part of these condensed consolidated interim financial statements

SOURCE: Aquarius Surgical Technologies Inc.

ReleaseID: 557723

NEW YORK, NY / ACCESSWIRE / August 28, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Carbonite, Inc. (NASDAQ:CARB)
Class Period: February 7, 2019 – July 25, 2019
Deadline: September 30, 2019
For more info: www.bgandg.com/carb

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Carbonite’s Server Backup VM Edition was of poor quality and technologically flawed; (2) Carbonite was receiving poor reviews and complaints from customers about the Server Backup VM Edition; (3) the poor quality and technological flaws of the Server Backup VM Edition were acting as a “disruptive” factor throughout the Carbonite salesforce and keeping that sales organization from closing opportunistically on several larger deals during fiscal 2019; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Cardinal Health, Inc. (NASDAQ:CAH)
Class Period: March 2, 2015 – May 2, 2018
Deadline: September 30, 2019
For more info: www.bgandg.com/cah

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements by stating that Cordis Corp., a medical device manufacturer that Cardinal Health acquired in March 2015, would benefit from its advanced inventory management and supply chain information technology solutions. The complaint also alleges that Defendants misleadingly represented that Cardinal Health properly “reserve[d] for inventory obsolescence” and that “[i]nventories presented in the consolidated balance sheets [were] net of reserves for excess and obsolete inventory.”

Just Energy Group Inc. (NYSE:JE)
Class Period: November 9, 2017 – July 23, 2019
Deadline: September 30, 2019
For more info: www.bgandg.com/je

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) that the Company experienced customer enrollment and nonpayment issues; (2) that, as a result, the Company was reasonably likely to incur an impairment charge to its accounts receivable; (3) that, as a result, the Company lacked adequate internal control over its financial reporting; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557348

NEW YORK, NY / ACCESSWIRE / August 28, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Oasmia Pharmaceutical AB (NASDAQ:OASM)
Class Period: October 23, 2015 – July 9, 2019
Deadline: September 27, 2019
For more info: www.bgandg.com/oasm

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Oasmia engaged in improper related-party transactions with Alceco International S.A. and Ardenia Investment LTD, which were controlled by Defendant Aleksov and his former father-in-law; (2) due to those transactions, millions of Swedish kronor were not accounted for in Oasmia’s books; (3) transactions concerning Oasmia’s patents were also “carried out in a doubtful way;” and (4) as a result of the aforementioned misconduct, defendants’ statements about Oasmia’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Eagle Bancorp, Inc. (NASDAQ:EGBN)
Class Period: March 2, 2015 – July 17, 2019
Deadline: September 27, 2019
For more info: www.bgandg.com/egbn

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Eagle’s internal controls and procedures and compliance policies were inadequate; (2) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for Eagle to undertake its own internal investigations; and (3) as a result, Eagle’s public statements were materially false and misleading at all relevant times.

3M Company (NYSE:MMM)
Class Period: February 9, 2017 – May 28, 2019
Deadline: September 27, 2019
For more info: www.bgandg.com/mmm

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) 3M’s vast internal evidence dating back decades confirmed that man-made chemicals or per- and polyfluoroalkyl substances (“PFAS”) are toxic (which was first publicly revealed in February 2018 by Minnesota’s Attorney General); (2) 3M had a long history of suppressing negative information and/or damaging data about PFAS; (3) 3M had significant legal exposure to state, county, and local governments and individuals around the country as a result of its knowledge and intentional concealment of the toxic harm caused by the use of PFAS; and (4) as a result, 3M’s public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557345

NEW YORK, NY / ACCESSWIRE / August 28, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Valaris plc (“Valaris” or “the Company”) (NYSE:VAL) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Valaris securities between April 11, 2019 and July 31, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/val.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Valaris was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (2) the foregoing was reasonably likely to have a material negative impact on Valaris’s second quarter 2019 results; (3) the merger leading to Valaris’s establishment could not deliver on its touted benefits; and (4) as a result, Valaris’s public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/val or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss Valaris you have until October 21, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557366

ROSEMONT, IL / ACCESSWIRE / August 28, 2019 / Leading industry companies have supported The ASSEMBLY Show, since its inception in 2013, and will continue to do so at the upcoming event October 22-24, 2019 at the Donald E. Stephens Convention Center in Rosemont, IL. With a focus exclusively on all thing’s “assembly”, charter sponsors have experienced the benefits of the events mission and commitment to helping suppliers, buyers and users of assembly equipment in manufacturing plants to connect, learn, share and explore. For more information, visit theassemblyshow.com.

“We thank all of the supporting companies and sponsors who help to make The ASSEMBLY Show such an important industry event. The staff of ASSEMBLY Magazine works year round to support the industry through our print and online publication and brings the industry together to Rosemont to meet face to face, see the products we write about, and network with industry leaders.” said Tom Esposito, Publisher, ASSEMBLY Magazine. “The ASSEMBLY Show is the place to connect and introduce products and services to a qualified audience of buyers and users of assembly equipment in manufacturing plants. We are very fortunate to have amazing support from the industry.”

The sponsors for the 2019 include Gold Sponsor Promess. Silver Sponsors are Schunk and Ingersoll Rand. Bronze Sponsors are Cincinnati Test Systems, Orbitform, and Schmidt Technology. In addition to the lead sponsors there are Education, Technology, Branding and Webinar Sponsors.

There will be two learning theaters on the show floor where subject matter experts will share their knowledge throughout the event. The Learning Theater Presentation Sponsors include Afag Automation, Balluff, Bosch Rexroth, Daifuku / Jervis B. Webb, DEPRAG, Desoutter, Dukane, eFlex Systems, Epson Robots, LACO Technologies, Sturtevant Richmont, Tutelar Technologies Inc, Ubisense, Universal Robots, and Weber Screwdriving Systems. For the full program, click here.

The ASSEMBLY Show and ASSEMBLY Magazine are offering a 3-part webinar series focusing on the next-generation of workers; envisioning an ideal plant; and lean six sigma in the age of artificial intelligence featuring leading subject matter experts. The Webinar Sponsors are ATI, BalTec, Design Tool Inc., Promess and Weiss. To learn more and register, click here.

There are over 30 Graphic Sponsors, some of which include AIMCO, Aries Engineering, Arthur G. Russell, ATC Automation, ATI, BalTec, Bostik, Built Systems, DEPRAG, Design Tool, Desoutter, eFlex Systems, EPSON Robots, Hoosier Feeder Company, INFICON, InterTech, Makita, Motion Index Drives, Nitto Seiko America, Nordson EFD, Orbitform, Panasonic Assembly Tools, Performance Feeders, Portescap, PrimeTest Automation, PROLINE, Promess, Schmidt Technology, Schunk, Sturtevant Richmont, Tohnichi, Ubisense, VKS, Weber Screwdriving Systems, Weiss, Wera Tools, Zimmer Group and more. Technology Sponsors include DEPRAG, Nordson EFD, and PATLITE. Branding Sponsors include ASG, Edgewater Automation, Hernon Manufacturing Inc., Nordson EFD, Panasonic Assembly Tools, Promess and RFID Inc.

The 7th Annual ASSEMBLY Show will bring together 8,000+ industry professionals with over 300 exhibiting companies and will be full of opportunities for manufacturing engineers and managers to uncover new resources, experience equipment hands-on, evaluate the latest technologies and products and connect face-to-face with industry experts.

The ASSEMBLY Show is sponsored by ASSEMBLY (www.assemblymag.com), a monthly trade magazine read by 56,000 engineers and managers responsible for manufacturing and designing cars, computers, catheters, coffee makers, etc. ASSEMBLY covers the processes, technologies and strategies for joining discrete parts into finished products. The event is produced by BNP Media (www.bnpmedia.com), one of the country’s leading business-to-business media companies serving professionals across 50+ industries. For more information, visit www.theassemblyshow.com.

# # #

For Further Information, Contact:

Amy Riemer, Media Relations Representative
978-475-4441 (office) or 978-502-4895 (cell)
amy@riemercommunications.com

SOURCE: The ASSEMBLY Show

ReleaseID: 557713